Clinical trials
Phase 3 Cholestasis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mirum Pharmaceuticals, Inc. | 4 |
| GlaxoSmithKline | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Albireo | 1 |
| Albireo, an Ipsen Company | 1 |
| Asan Medical Center | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Coordinación de Investigación en Salud, Mexico | 1 |
| Kapiolani Medical Center For Women & Children | 1 |
| Medical University of Graz | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholestasis | 19 |
| Liver Cirrhosis, Biliary | 4 |
| Liver Diseases | 4 |
| Hyperphagia | 3 |
| Pruritus | 3 |
| Bile Duct Diseases | 2 |
| Biliary Tract Diseases | 2 |
| Cholangitis, Sclerosing | 2 |
| Digestive System Diseases | 2 |
| Premature Birth | 2 |
Trials
Showing 76 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.